Anavex Life Sciences Corp. (OTCQX: AVXL) is a clinical-stage biopharmaceutical company engaged in the development of drug candidates to treat Alzheimer’s disease, other CNS diseases and various types of cancer, according to the company's website (see here: www.Anavex.com) SNNLive caught up with Christopher U. Missling, PhD, President & CEO of Anavex Life Sciences Corp. at the Marcum MicroCap Conference 2015 in New York City, NY.
Dr. Missling begins with a brief overview of Anavex Life Sciences, “Anavex is targeting one of the most difficult diseases, which is Alzheimer’s. We have various compounds for this indication, and we are a small company now in the middle of clinical trial in Alzheimer’s Disease.” He continues with an update on the Company’s clinical trial, where and why they are doing the trial in Australia, and the scientific explanation of how the drug works for the Alzheimer’s indication.
Dr. Missling goes on to discuss whether the Company’s drug is showing indications as preventative or a reversal of the disease, the size of the market (how many people affected and cause), and why has it taken so long for a company to start working on developing treatments for Alzheimer’s.
Since speaking with Dr. Missling, the Company has made the following announcements:
For more information about Anavex Life Sciences Corp., go to: www.Anavex.com
© 2017 Stock News Now
Supported by Superior Web Solutions